The most accessed healthcare professional in most markets is not the physician. It is the community pharmacist.
The most trusted healthcare professional on medication questions is not the physician. It is the community pharmacist.
The most under engaged stakeholder in pharma's commercial strategy is also the community pharmacist.
This gap is structural, well documented, and has barely moved despite a decade of omnichannel pharma marketing investment.
The Access Data
In the United States, a JAMA Network Open analysis of 681,456 Medicare beneficiaries found that community pharmacy visits outnumbered primary care physician encounters by nearly two to one. The median patient made 13 pharmacy visits per year versus 7 PCP encounters. In rural areas, the gap widened to 14 pharmacy visits versus 5 PCP encounters.
Almost 90 percent of Americans live within 5 miles of a community pharmacy. The CVS Health 2025 Rx Report found that 88 percent of consumers believe pharmacists are the most accessible and frequently visited healthcare providers. The Wolters Kluwer Pharmacy Next survey found that 58 percent of Americans would first seek non emergency healthcare at a pharmacy rather than a physician's office.
Wales offers a clean policy level data point. Between April 2024 and March 2025, Welsh community pharmacy services delivered over 462,000 consultations for common ailments. That is a 34.4 percent increase year over year and a 506.6 percent increase compared to five years ago. The shift toward pharmacy as a primary access point is not theoretical. It is already happening at scale.
The Trust Data
Patients do not just visit pharmacists more often. They trust them differently.
The BrandSpark American Pharmacists Trust Study 2024 found that 84 percent of consumers trust their healthcare provider's advice on which OTC medicine to take. Separate research from the Wolters Kluwer survey found that 81 percent of Americans trust a pharmacist, nurse, or nurse practitioner to diagnose minor illnesses and prescribe medications to treat them.
The trust gap converts. A pharmacist recommendation translates to purchase behavior at a rate that physician recommendations rarely match in OTC and self care categories.
The MENA Reality
In Egypt, the picture is sharper still.
A 2023 review published in PMC documented 95,000 community pharmacies operating in Egypt, with registered pharmacists rising from 71,000 in 2003 to 313,000 by 2023. In dense urban areas, Egyptian regulations allow pharmacies to operate as close as 100 meters apart.
The same review found that Egyptian community pharmacists influence four out of ten pharmaceutical purchase decisions. The influence concentrates in lower socioeconomic neighborhoods, where pharmacists informally deliver primary care including diagnosis, patient education, lifestyle counseling, and physician referrals.
Despite this scale, Egypt has no national self care strategy and no formal programs supporting community pharmacists in this expanded role. The infrastructure exists. The institutional recognition does not.
The pattern repeats across the GCC and broader MENA. A 2025 scoping review in the International Journal of Pharmacy Practice on community pharmacy services across GCC countries documented high accessibility paired with inconsistent pharmaceutical care implementation.
The Marketing Spend Mismatch
Now look at where pharma actually puts its commercial budget.
Global pharma marketing spend is approximately 90 billion dollars annually, with top companies reinvesting 20 to 30 percent of revenue into combined marketing and sales. Within that, HCP marketing typically takes 47 to 53 percent of digital spend, and HCP channels overall account for 65 to 80 percent of brand level marketing investment because of the prescription leverage HCPs hold.
Inside the HCP bucket, physicians command the lion's share. Pharmacists are grouped with nurses, advocacy groups, investors, and caregivers in industry reporting, with allocations that have remained roughly flat while physician spend has increased.
In a 2025 environment where pharma publicly commits to omnichannel engagement, the single most accessed and most trusted HCP segment is the one receiving the least concentrated marketing investment.
Why Pharma Keeps Missing This
Three reasons.
First, pharma's commercial model was designed for the physician led prescription era. That era is shifting toward team based care, OTC self management, and shared decision making. The budget allocation has not caught up with the channel reality.
Second, pharmacists are harder to segment, target, and measure. Physicians produce clear prescription data. Pharmacist influence happens in conversation, at point of sale, in the moment a patient asks which medicine to take. There is no clean industry equivalent for tracking pharmacist persuasion.
Third, the relationship is held by retail pharmacy chains, not by pharma brands. CVS, Walgreens, Boots, and major MENA chains own the pharmacist relationship. Pharma's traditional sales force is built to bypass the pharmacy rather than engage through it.
What Changes When You Correct It
The companies that figure out pharmacist engagement first will gain three advantages.
First, they reach the actual decision moment. A meaningful share of healthcare decisions happens at the pharmacy counter, not the prescriber's office. Engaging the pharmacist before the patient arrives shifts which product gets recommended.
Second, they capture self care market share. As more health conditions migrate to OTC and behind the counter formats, pharmacist preference matters more for revenue.
Third, they gain credibility with policymakers. Health authorities across the EMR and the EU are formally recognizing the expanded pharmacist role. The pharma companies that have invested in the relationship are positioned to influence policy direction. The ones that have not will be reacting to it.
The Implication
The most accessed, most trusted, most influential healthcare professional in most markets is sitting outside the center of pharma's commercial strategy.
This is not a near term gap. It is an aging gap that the industry has not closed in twenty years, and the channels are reshaping faster than the budget is.
The first pharma companies to take pharmacist engagement seriously will not announce it. They will quietly outperform across self care, OTC, and retail driven categories while the rest of the industry keeps refining its physician targeted dashboards.
The pharmacist is the stakeholder pharma forgot. The reckoning is already in the data.
